Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2023, titled "Zydus receives USFDA approval for ZITUVIMETTM to treat adult patients with type 2 diabetes mellitus".
Zydus Lifesciences Limited Press Release Nov 06 2023
Filed with NSE · · 8 pages · English
Summary by 6ix AI
The approval is based on the company's New Drug Application for ZITUVIMET, which combines sitagliptin and metformin hydrochloride. This drug aims to improve glycemic control in adults and is compliant with current USFDA standards. The approval is expected to enhance accessibility and affordability of diabetes treatment options.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Nov 03 2023
- Press Release Nov 02 2023
- Press Release Oct 31 2023
- Press Release Oct 30 2023
- Press Release Oct 25 2023
Later from Zydus Lifesciences
- Press Release Nov 07 2023
- Press Release Nov 10 2023
- Press Release Dec 01 2023
- Zydus Lifesciences Limited Press Release Dec 06 2023
- Zydus Lifesciences Limited Press Release Dec 11 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences